Paul Allen's Vulcan Capital to Invest in Omeros Biotechnology Drug Program

Omeros Corp. rose in Nasdaq trading after Vulcan Capital, billionaire Paul Allen’s investment group, invested $20 million in the Seattle biotechnology company that is developing drugs to treat inflammatory and nervous-system disorders.

Omeros will also receive a $5 million grant from the state of Washington’s Life Sciences Discovery Fund, according to a company statement today. Vulcan and the life sciences fund will receive a percentage “in the mid-teens” from any sales generated by the drugs, as well as stock warrants, according to the statement. Omeros gained 93 cents, or 13 percent, to $8.23 at 4 p.m. New York time in Nasdaq Stock Market composite trading.

The funds from Vulcan and Washington state will support Omeros’s research to identify promising compounds that home in on a class of common drug targets known as G protein-coupled receptors, or GPCRs. Omeros’s most-advanced experimental drugs are designed to treat inflammation during surgery, according to the Omeros website.

“Omeros’s GPCR platform has the potential to accelerate new pipeline development across a broad range of highly attractive drug targets and can make a significant impact,” Steve Hall, Vulcan Capital’s managing director, said in the statement.

To contact the reporter on this story: David Olmos in San Francisco at dolmos@bloomberg.net

To contact the editor responsible for this story: Reg Gale at Rgale5@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.